These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 27344724)

  • 1. [Prognostic factors in patients with castration-resistant prostate cancer].
    Furuse H; Ozono S
    Nihon Rinsho; 2016 May; 74 Suppl 3():171-5. PubMed ID: 27344724
    [No Abstract]   [Full Text] [Related]  

  • 2. Prognostic and predictive biomarkers in metastatic castration-resistant prostate cancer.
    Armstrong AJ
    Clin Adv Hematol Oncol; 2017 Mar; 15(3):184-188. PubMed ID: 28398272
    [No Abstract]   [Full Text] [Related]  

  • 3. [Biomarkers in metastatic castration-resistant prostate cancer].
    Miller K
    Aktuelle Urol; 2015 Jan; 46(1):66-70. PubMed ID: 25658233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. There is no current role for molecular phenotyping in metastatic castrate-resistant prostate cancer.
    Vogelzang NJ
    Clin Adv Hematol Oncol; 2015 Sep; 13(9):580-5. PubMed ID: 26452189
    [No Abstract]   [Full Text] [Related]  

  • 5. [Evaluation and diagnosis for castration resistant prostate cancer: CRPC].
    Kamoto T
    Nihon Rinsho; 2014 Dec; 72(12):2103-7. PubMed ID: 25518341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Durable complete remission from castration-resistant prostate cancer with sipuleucel-T after estrogen withdrawal.
    Dorff TB; Wilkins C; Hepgur M; Quinn DI
    Clin Genitourin Cancer; 2014 Apr; 12(2):e55-8. PubMed ID: 24331572
    [No Abstract]   [Full Text] [Related]  

  • 7. Is computed tomography a necessary part of a metastatic evaluation for castration-resistant prostate cancer? Results from the Shared Equal Access Regional Cancer Hospital Database.
    Hanyok BT; Howard LE; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Posadas EM; Freedland SJ
    Cancer; 2016 Jan; 122(2):222-9. PubMed ID: 26484853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The time for molecular phenotyping of metastatic castrate-resistant prostate cancer is now.
    VanderWeele DJ
    Clin Adv Hematol Oncol; 2015 Sep; 13(9):580-3. PubMed ID: 26452188
    [No Abstract]   [Full Text] [Related]  

  • 9. Practice patterns and predictors of followup imaging after a negative bone scan in men with castration resistant prostate cancer: results from the SEARCH database.
    Sourbeer KN; Howard LE; Moreira DM; Amarasekara HS; Chow LD; Cockrell DC; Hanyok BT; Pratson CL; Kane CJ; Terris MK; Aronson WJ; Cooperberg MR; Amling CL; Hernandez RK; Freedland SJ
    J Urol; 2015 Apr; 193(4):1232-8. PubMed ID: 25463986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. When to initiate treatment with radium-223 in patients with metastatic castration-resistant prostate cancer.
    Shore ND
    Clin Adv Hematol Oncol; 2016 Jan; 14(1):26-9. PubMed ID: 27057663
    [No Abstract]   [Full Text] [Related]  

  • 11. New developments in the imaging of metastatic prostate cancer.
    Beauregard JM; Pouliot F
    Curr Opin Support Palliat Care; 2014 Sep; 8(3):265-70. PubMed ID: 25004180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancer.
    Li J; Armstrong AJ
    Clin Adv Hematol Oncol; 2015 May; 13(5):293-8. PubMed ID: 26352773
    [No Abstract]   [Full Text] [Related]  

  • 13. Biomarkers in castration-resistant prostate cancer.
    Armstrong AJ
    Clin Adv Hematol Oncol; 2014 Feb; 12(2):115-8. PubMed ID: 24892256
    [No Abstract]   [Full Text] [Related]  

  • 14. The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer.
    Pond GR; Sonpavde G; de Wit R; Eisenberger MA; Tannock IF; Armstrong AJ
    Eur Urol; 2014 Jan; 65(1):3-6. PubMed ID: 24120464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening of visceral metastasis in castration-resistant prostate cancer: a cornerstone in personalized patient's care.
    Grobet-Jeandin E; Valerio M
    Prostate Cancer Prostatic Dis; 2023 Mar; 26(1):3-4. PubMed ID: 36203050
    [No Abstract]   [Full Text] [Related]  

  • 16. miR-663 induces castration-resistant prostate cancer transformation and predicts clinical recurrence.
    Jiao L; Deng Z; Xu C; Yu Y; Li Y; Yang C; Chen J; Liu Z; Huang G; Li LC; Sun Y
    J Cell Physiol; 2014 Jul; 229(7):834-44. PubMed ID: 24243035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone Scan Index predicts outcome in patients with metastatic hormone-sensitive prostate cancer.
    Poulsen MH; Rasmussen J; Edenbrandt L; Høilund-Carlsen PF; Gerke O; Johansen A; Lund L
    BJU Int; 2016 May; 117(5):748-53. PubMed ID: 25906907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in systemic therapies for metastatic castration-resistant prostate cancer.
    Pant MK; Abughaban A; Aragon-Ching JB
    Future Oncol; 2014 Nov; 10(14):2213-26. PubMed ID: 25471035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current role of cabozantinib in metastatic castration-resistant prostate cancer.
    Fay AP; Albiges L; Bellmunt J
    Expert Rev Anticancer Ther; 2015 Feb; 15(2):151-6. PubMed ID: 25586337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is prostate cancer changing?: evolving patterns of metastatic castration-resistant prostate cancer.
    Doctor SM; Tsao CK; Godbold JH; Galsky MD; Oh WK
    Cancer; 2014 Mar; 120(6):833-9. PubMed ID: 25302607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.